Skip to main content

Table 7 First-Line Options for On-Demand Treatment of HAE-1/2

From: WAO Guideline for the Management of Hereditary Angioedema

 

Route of administration

Efficacy

Safety

Limitation

Self-administration

Age, yrs

Cost

Berinert

IV

+++

+++*

+†

+

All (≥12 in the United States)

High

Cinryze

IV

+++

+++*

+†

+

≥12

High

Ruconest

IV

+++

+++

+‡

-

≥18

High

Icatibant

SC

+++

+++

+§

+

≥18

High

Ecallantide

SC

+++

+++

+||

-

> 16

High

  1. IV, intraveneous; SC, subcutaneous.
  2. *Blood product.
  3. †Pretreatment vaccination recommended.
  4. ‡Pretreatment and repeated allergological testing required.
  5. §Special attention required in acute ischemic heart disease/unstable angina and in the first week after cerebral infarction.
  6. ¶Three injections.
  7. ||Posttreatment observation/keep refrigerated.